SJEPD028_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 5.88
- e1_e2
- E2
- umap1_2d
- -6.179413383
- umap2_2d
- -0.913770343
- umap1_3d
- 0.877140746
- umap2_3d
- 2.794640121
- umap3_3d
- 0.803982805
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.410
- MYOGENESIS+0.410
- KRAS_SIGNALING_DN+0.320
- COAGULATION+0.300
- BILE_ACID_METABOLISM+0.290
- XENOBIOTIC_METABOLISM+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- ANGIOGENESIS+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- ESTROGEN_RESPONSE_LATE+0.170
Top 10 suppressed
- PROTEIN_SECRETION-0.530
- MYC_TARGETS_V1-0.500
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.430
- MTORC1_SIGNALING-0.400
- ANDROGEN_RESPONSE-0.390
- MITOTIC_SPINDLE-0.380
- MYC_TARGETS_V2-0.370
- PI3K_AKT_MTOR_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD035_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.914 |
| 2 | 60c210ff-d245-40d2-9de9-7b799cc3ffc9 | — | — | 0.899 |
| 3 | SRR5903552 | — | cohortA1 | 0.877 |
| 4 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.859 |
| 5 | d93b1580-c20d-4611-ac99-c0cb33f37a45 | — | — | 0.859 |
| 6 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.857 |
| 7 | SJEPD001515_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.852 |
| 8 | SJEPD001525_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.851 |
| 9 | SRR1443895 | GTEX | — | 0.850 |
| 10 | SJEPD005_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |